Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Appoints Iron Mountain CEO Richard Reese to Board of Directors

WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 3, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that Richard Reese, Chairman and Chief Executive Officer at Iron Mountain Incorporated (NYSE: IRM) was elected to the organization's Board of Directors. Mr. Reese's experience growing Iron Mountain into a multi-billion dollar, global industry leader will strengthen the board's ability to execute on Charles River Laboratories' corporate strategy.

"Similar to Iron Mountain, Charles River's focus on customer service and innovation are pillars of our market leadership," said James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories. "Richard's brilliance in understanding and meeting the needs of the marketplace will be invaluable in guiding our future. His extensive experience, entrepreneurial spirit and proven track record make him a welcomed addition to the board."

Richard Reese joined Iron Mountain as president in 1981 when the company was regional and privately held, with only $3 million in annual revenue. Under his leadership, Iron Mountain has developed into a global company with more than $2.5 billion in revenue, providing comprehensive services and expertise to help its more than 100,000 corporate customers solve their most complex information protection and storage challenges.

Iron Mountain debuted on the Fortune 1000 list in 2003 at number 887 and has climbed steadily to 780 in 2007. This extraordinary growth and execution on strategy earned Mr. Reese accolades from Ernst & Young in 2003, which named him a "New England Entrepreneur of the Year."

A true believer in entrepreneurship, prior to joining Iron Mountain, Mr. Reese lectured on the topic at Harvard Business School and provided consulting services to small- and medium-sized emerging companies. He is also the former president and director of PRISM International, a trade association of records management companies.

"Working with an organization that is helping to create a future where people enjoy healthier lives is extremely rewarding," said Richard Reese, Chairman and Chief Executive Officer of Iron Mountain. "I am also excited to join the board in a year where the organization celebrates 60 years of innovation. I look forward to helping the board and management chart the course for the next 60 years of success."

About Charles River Laboratories

Charles River Laboratories based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies, government agencies and leading academic institutions to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 8,300 employees serve clients worldwide. For more information on Charles River, visit our website at www.criver.com.

Caution Concerning Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements include the statements in this press release regarding future demand for drug discovery and developments products and services, including the outsourcing of these services; the specific contributions of members of Charles River's Board of Directors; and expectations regarding market and industry conditions. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2007, as well as other filings we make with the Securities and Exchange Commission. Charles River assumes no obligation and expressly disclaims any duty to update information contained in this release except as required by law.

CONTACT: Charles River Laboratories
Amy Cianciaruso, 781-222-6168
amy.cianciaruso@crl.com

SOURCE: Charles River Laboratories International, Inc.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)